Trial Profile
ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; LHRH receptor agonists
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARCHES
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 21 Mar 2024 The trial has been completed in Sweden, according to European Clinical Trials Database.
- 17 Mar 2024 The trial has been completed in Finland, according to European Clinical Trials Database.
- 08 Mar 2024 This trial has been Completed in France, According to European Clinical Trials Database record.